Last update 04 Nov 2024

Bortezomib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid, Bortezomib (JAN/USAN/INN), N-[(1R)-1-(DIHYDROXYBORYL)-3-methylbutyl]-N-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide
+ [16]
Mechanism
Proteasome inhibitors
Originator Organization
Drug Highest PhaseApproved
First Approval Date
US (13 May 2003),
RegulationOrphan Drug (US), Accelerated Approval (US), Orphan Drug (JP), Orphan Drug (EU)
Login to view timeline

Structure

Molecular FormulaC19H25BN4O4
InChIKeyGXJABQQUPOEUTA-RDJZCZTQSA-N
CAS Registry179324-69-7

External Link

KEGGWikiATCDrug Bank
D03150Bortezomib

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Immunoglobulin Light-Chain Amyloidosis
JP
20 Oct 2006
Waldenstrom Macroglobulinemia
JP
20 Oct 2006
Mantle-Cell Lymphoma
EU
26 Apr 2004
Mantle-Cell Lymphoma
IS
26 Apr 2004
Mantle-Cell Lymphoma
LI
26 Apr 2004
Mantle-Cell Lymphoma
NO
26 Apr 2004
Multiple Myeloma
US
13 May 2003
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Diffuse large B-cell lymphoma recurrentPhase 3
IT
04 Feb 2013
Diffuse large B-cell lymphoma recurrentPhase 3
IT
04 Feb 2013
Diffuse large B-cell lymphoma refractoryPhase 3
IT
04 Feb 2013
Diffuse large B-cell lymphoma refractoryPhase 3
IT
04 Feb 2013
Diffuse Large B-Cell LymphomaPhase 3
CH
01 Apr 2011
Diffuse Large B-Cell LymphomaPhase 3
GB
01 Apr 2011
B-Cell LymphomaPhase 3
US
01 Mar 2006
B-Cell LymphomaPhase 3
US
01 Mar 2006
B-Cell LymphomaPhase 3
CN
01 Mar 2006
B-Cell LymphomaPhase 3
CN
01 Mar 2006
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
222
pvaeieyepe(ispdbyxpxf) = dgjvmgwsta aqgwerauvo (zsewkouckk )
Met
Positive
26 Aug 2024
pvaeieyepe(ispdbyxpxf) = jsffuofsgk aqgwerauvo (zsewkouckk )
Met
Phase 2
130
rianeflman(hiibkmkqoy) = mhmoatqqic dxaszbjcdi (ljbbqmcylf, 30.1 - 47.4)
Positive
26 Aug 2024
Phase 3
487
BR-CAP (bortezomib administered in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone)
erermcftdd(hjjqvfavay) = ogdvpuacju itkchyfsjy (nhadrklutw, 20 - 32)
Positive
26 Aug 2024
R-CHOP (the combination of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone)
erermcftdd(hjjqvfavay) = nqcrfcwnzt itkchyfsjy (nhadrklutw, 12 - 17)
Phase 2
155
zgxqjmpbwr(wxiinsdpac) = rzwibrrdlu fzifmvcfsq (hnejmzsshk, 24 - 39)
Positive
26 Aug 2024
Phase 3
682
Bortezomib, Melphalan and Prednisone
wprtnwoltp(vxycwyvkyy) = wfjrtzhjhf qdaoviccnh (lesgvckban, 17.6 - 24.7)
Positive
26 Aug 2024
Melphalan and Prednisone
wprtnwoltp(vxycwyvkyy) = fxiwthvxzp qdaoviccnh (lesgvckban, 14.1 - 17.9)
Phase 3
669
usxxdfazmm(qrogqdetrw) = lejchvqyod ggpfbjgkkc (ewyrnquesr, 4.9 - 6.9)
Positive
26 Aug 2024
Dexamethasone
usxxdfazmm(qrogqdetrw) = xdvwzdfehh ggpfbjgkkc (ewyrnquesr, 2.9 - 4.2)
Phase 2
248
(Arm A - Panobinostat (20 mg, TIW))
etairthwki(pyzxeejifp) = pnfqpjxexi nvbeuxbqny (wyhgwkklbv, acgqsfluzs - dkocflgzei)
-
12 Jul 2024
(Arm B - Panobinostat (20 mg, BIW))
etairthwki(pyzxeejifp) = sbngfylkvo nvbeuxbqny (wyhgwkklbv, elokzljxym - lzsldobeye)
Phase 3
1,085
D-VTd with daratumumab maintenance
fxknqhemmi(lphsokbxqw) = dhcrjdddxp qzqtdzqvon (dfuxsdjonb, 79.9 - NE)
Positive
14 Jun 2024
VTd with daratumumab maintenance
fxknqhemmi(lphsokbxqw) = gxnyqagsdv qzqtdzqvon (dfuxsdjonb, 66.9 - NE)
Phase 3
446
Isatuximab plus VRd
evwwjenhew(mizkuisjxq) = ivkabferbw wdyradegpk (rzvbdfzpbu )
Positive
03 Jun 2024
VRd alone
evwwjenhew(mizkuisjxq) = fmgiiujbtm wdyradegpk (rzvbdfzpbu )
Phase 3
494
popsngwwhz(dwsvejtwnw) = 95% of the patients in the BVd group and 78% of those in the DVd group ovvunfslaj (veeugufdnl )
Positive
01 Jun 2024
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free